A Randomized, Open-Label, Parallel-Controlled, Multicenter Phase III Clinical Trial to Evaluate the Safety and Efficacy of Anlotinib Hydrochloride Combined with Benmelstobart versus Toripalimab Combined with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma Harboring Specific Gene Mutations
Hemoglobin ≥90 g/L;
Absolute neutrophil count (ANC) ≥1.5 × 10^9/L;
Platelets ≥75 × 10^9/L;
Total bilirubin ≤1.5 × upper limit of normal (ULN);
New York Heart Association (NYHA) Class II or greater heart failure or left ventricular ejection fraction (LVEF) <50% by echocardiography;
History of clinically significant ventricular arrhythmia (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes) or arrhythmia requiring continuous antiarrhythmic medication;
Unstable angina pectoris;
Myocardial infarction within 12 months;